Company intelligence / Profile preview

HarborSite

Cambridge, Massachusetts, United States

Ownership: Private
Development stage: Other

Overview

Harbor Biomedicines has developed the "HarborSite" technology, which uses engineered recombinases to enable precise, efficient integration of large DNA cargos into genomic safe harbors. This approach aims to provide robust, durable expression of therapeutic genes with an initial focus on curative treatments for rare genetic and common disorders affecting the liver and blood cells. The company’s work remains in pre-clinical development.[1][6]

Therapeutic areas: HematologyRare Diseases
Modalities: Gene therapy
Industry: Biotech

Beyond the preview

Go deeper on HarborSite.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HarborSite.

Explore the full profile